Item request has been placed!

Item request cannot be made.

Processing Request

نتائج البحث

Display Settings

النتائج لكل صفحة: 10

Sort By: Relevance

Filter

فلترة النتائج

Publication : haemophilia

إعادة تعيين خيارات الفبترة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada

Authors : Matino, Davide¹ (AUTHOR) ; Germini, Federico^1,2 (AUTHOR); Chan, Anthony K. C.³ (AUTHOR)

Source: Haemophilia. Mar2024, Vol. 30 Issue 2, p345-354. 10p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Clinical experience with moroctocog alfa (AF‐CC) in younger paediatric patients with severe haemophilia A: Two open‐label studies.

Authors : Rusen, L.¹; Kavakli, K.²; Korth‐Bradley, J.³

Source: Haemophilia. Jul2018, Vol. 24 Issue 4, p604-610. 7p. 4 Charts, 1 Graph.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Recombinant porcine sequence factor VIII (rp FVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.

Authors : Tarantino, M. D.¹; Cuker, A.²; Hardesty, B.³

Source: Haemophilia. Jan2017, Vol. 23 Issue 1, p25-32. 8p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Haemate® P/Humate-P® for the treatment of von Willebrand disease: considerations for use and clinical experience.

Authors : AUERSWALD, G.¹ ; KREUZ, W.²

Source: Haemophilia. Nov2008 Supplement 5, Vol. 14, p39-46. 8p. 2 Charts, 2 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.

Authors : MATYSIAK, M.¹; BOBROWSKA, H.²; BALWIERZ, W.³

Source: Haemophilia. Sep2011, Vol. 17 Issue 5, p737-742. 6p. 7 Charts.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Haemate® P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.

Authors : SCHRAMM, W.¹

Source: Haemophilia. Nov2008 Supplement 5, Vol. 14, p3-10. 8p. 1 Black and White Photograph, 1 Diagram.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Authors : MORFINI, M.¹ ; AUERSWALD, G.²; KOBELT, R. A.³

Source: Haemophilia. Sep2007, Vol. 13 Issue 5, p502-507. 6p. 2 Charts, 1 Graph.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases.

Authors : Y.-w. Huang¹ ; Saidi, P.¹; Philipp, C.¹

Source: Haemophilia. Nov2004, Vol. 10 Issue 6, p713-721. 9p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.

Authors : Stieltjes, N.¹ ; Altisent, C.²; Auerswald, G.³

Source: Haemophilia. Sep2004, Vol. 10 Issue 5, p452-458. 7p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Efficacy and safety of a factor VIII–von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.

Authors : Lubetsky, A.¹; Martinowitz, U.¹; Luboshitz, J.¹

Source: Haemophilia. Sep2002, Vol. 8 Issue 5, p622-628. 8p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada

Clinical experience with moroctocog alfa (AF‐CC) in younger paediatric patients with severe haemophilia A: Two open‐label studies.

Recombinant porcine sequence factor VIII (rp FVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.

Haemate® P/Humate-P® for the treatment of von Willebrand disease: considerations for use and clinical experience.

Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.

Haemate® P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases.

Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.

Efficacy and safety of a factor VIII–von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.

اتصل بنا

اتبع